Graier, T., Salmhofer, W., Jonak, C., Weger, W., Kölli, C., Gruber, B., Sator, P., Prillinger, K., Mlynek, A., Schütz‐Bergmayr, M., Richter, L., Ratzinger, G., Painsi, C., Selhofer, S., Häring, N., Wippel‐Slupetzky, K., Skvara, H., Trattner, H., Tanew, A., Inzinger, M., Tatarski, R., Bangert, C., Ellersdorfer, C., Lichem, R., Gruber‐Wackernagel, A., Hofer, A., Legat, F., Schmiedberger, E., Strohal, R., Lange‐Asschenfeldt, B., Schmuth, M., Vujic, I., Hoetzenecker, W., Trautinger, F., Saxinger, W., Müllegger, R., Quehenberger, F., & Wolf, P. (2021). biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*. British journal of dermatology, 184, 1094–1105. http://access.bl.uk/ark:/81055/vdc_100172211752.0x000038